homology from other species (PE3), or gene models (PE4) (MPs), which have declined from 5511 in 2012 to 2129 in 2019. Splice variants, sequence variants, and some posttranslational modifications (PTMs) are tabulated for each protein entry 8 . We acknowledge that neXtProt continues to carry a category PE5, which represents dubious or uncertain genes, including many pseudogenes. However, the HPP in 2013 removed PE5 from the denominator of all predicted proteins to be found 3 and excluded these from the MP-50
As shown at the bottom of Table 1 , there has been a corresponding increase in the number of proteins in the human build of PeptideAtlas. PeptideAtlas provides an essential HPP function by uniformly processing raw MS data/metadata registered in ProteomeXchange through its Trans-Proteomic Pipeline (TPP) [9] [10] and applying the communally-agreed HPP Guidelines 2.1 for Interpretation of Mass Spectrometry Data 11 .
The number of proteins in PeptideAtlas that are assessed as canonical has increased from 12 509 to 16 293, despite the implementation of more stringent guidelines, which accounts for the observed dip between 2014 and 2016. We present the main sources of the increment of 495 canonical proteins from 2018 to 2019 in Figure 3 , below. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 In Figure 1 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 of what has been termed the "Dark Proteome" (DP) 13 . 
Progress from the Chromosome-centric C-HPP
The C-HPP initiated a Next-MP50 challenge at the Sun Moon Lake Workshop following the Taipei HUPO Congress in 2016. The aim was to galvanize the 24 chromosome teams to each find 50 missing proteins as a step toward completing the human proteome parts list. As shown in Table 2 , that 50 MP target has been reached for Chromosomes 19, 1, 5, and 17. Chromosomes 2, 3, 10, and X have 43 to 47 net reduction of MPs. The Chr 17 team has published detailed analyses of the paths to reduce PE2,3,4 and increase PE1 [14] [15] . As depicted for the whole proteome in Figure 2 flowcharts, the dynamics of promoting, demoting, gaining, and deleting protein entries in neXtProt is quite complex.
More detailed chromosome-by-chromosome analyses are planned for the coming year.
C-HPP investigators generated 10 articles for the 6th annual HPP Special Issue of J unusual/rare/stressed tissues 26 Examples include organ-specific endothelium, hard connective tissues with cartilaginous structures and cortical versus trabecular versus membranous bones 28 , dental tissues like dentin and odontoblasts 29 , and brain regions. In embryonic tissues, limited bursts of transcription factor expression and specific hydrolases likely account for many differentiating aspects of each cell and tissue in the body. Identifying such temporally or spatially rare proteins will require dedicated searches at precise developmental windows-an ethical and practical challenge. Likewise, tissue responses to bacterial, viral, and parasitic infections, or after injury may harbor MPs key for regeneration or repair 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 of these specific tissues. Integration with the B/D-HPP teams in this task is highly desirable.
Meanwhile, the C-HPP initiated the neXt-CP50 challenge for the functional characterization of the dark proteome, that is, human proteins with no known or inferred 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 16 predict functions of uPE1 proteins using I-TASSER and COFACTOR was introduced by the Chromosome 17 team 32 and subjected to blinded analyses of newly annotated proteins in CAFA3 and in neXtProt-2019 33 .
Newly Identified Canonical Proteins in Peptide Atlas
PeptideAtlas [34] [35] reprocessed and incorporated data from 120 new human sample datasets between the 2018-01 and 2019-01 builds. Not all newly deposited and released MS datasets are automatically captured and incorporated into PeptideAtlas because, with each additional dataset, the stringency applied to all data must be increased to maintain a constant false discovery rate (FDR). Thus, only datasets that are sufficiently novel are subjected to TPP reanalysis and are incorporated. These additional MS data resulted in an increase in the number of PeptideAtlas proteins for which there are at least two uniquely-mapping, non-nested 9+ amino acid peptides by 495 to a 2019-01 count of 16 293 (Table 1) . Figure 3 depicts the contributions of the top 10 datasets to this increase in the number of proteins, accounting for 292 (59%) of the 495. The three datasets contributing the most canonical proteins (a total of 161) were PXD009737 36 , 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 PXD010630 37 , and PXD009840 24 , all resulting from the 6 th HPP special issue in this journal (2018). It is impressive that major progress has been made with membrane proteins. The PeptideAtlas reanalysis of data from the use of multiple proteases by Sun et al 36 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 19 middle are the proteins classified as PE1 in neXtProt based on evidence from other techniques (see Figure 1 and associated text); this number has been steadily decreasing over the past four years. In red on the right are the PE2,3,4 MPs. The total has been increasing at a small rate as understanding and annotation of the human proteome improves each year. A simple extrapolation of increases in green and decreases in yellow and red (based on 2016 to 2019 data) yields a convergence of all three on the year 2026.
Clearly, additional strategies need to be developed to accelerate progress to reach nearcomplete human proteome coverage at a stringency required by the HPP Mass Spectrometry Data Interpretation Guidelines 3.0 (see below). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 21 Mass Spectrometry Data Interpretation Guidelines 2.1 11 and implementation of the workflow by which the HPP confirms the translation of potential coding genes. Each of these questions was debated, potential solutions listed, and consensus decisions achieved by the participants. The result will be an update of the Guidelines from version 2.1 to version 3.0, with a manuscript 48 describing the set of questions, potential solutions, proposed consensus decisions, and the logic behind those proposals. For the checklist required for submitted manuscripts, numbered items will be re-factored into logical subgroups and authors will be required to provide page numbers on the checklist so reviewers can see where specific guidelines are addressed in the manuscripts. The term "extraordinary detection claims," which appears to have caused some confusion, will be replaced with "new PE1 protein detection claims." The revised guidelines will refine how peptide nesting is defined and specify how sequence-identical protein entries should be handled.
Two new guidelines will be added: (1) the provision of Universal Spectrum Identifiers (USI; http://psidev.info/USI), a feature developed by the HUPO Proteomics Standards
Initiative (PSI) that enables the unique identification of a particular spectrum being held 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 22 up as evidence for a new PE1 protein detection claim across proteomics repositories, suitable for searching; and (2) a guideline for handling HPP datasets that use dataindependent acquisition (DIA) workflows including SWATH-MS 49 . These guideline changes are expected to take effect for contributions to the 2020 JPR HPP Special Issue.
At the workshop, several changes to the overall pipeline for tracking detections of MPs were considered. The current pipeline begins with deposition to ProteomeXchange, reprocessing of datasets by PeptideAtlas, and final mapping and incorporation by neXtProt. It was agreed that there would be no substantial change to the basic set of guidelines for calling a protein successfully identified by mass spectrometry. However, the meaning of the terms non-nested and uniquely-mapping has been interpreted and implemented in slightly different ways among the different components of the pipeline. A consensus interpretation was clarified and will be documented.
For proteins that come close to meeting the guidelines, but do not meet them due to their extreme sequence composition (e.g., very short or very hydrophobic), it was decided that complex exception rules are not warranted. Rather, a panel of researchers including neXtProt curators will be established to review evidence for special cases and classify 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 
ProteomeXchange (PX)
The ProteomeXchange Consortium 51 was founded a decade ago by the European Bioinformatics Institute (EBI) and HUPO based on PRIDE and PeptideAtlas. As of 23 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 25 via ProteomeXchange to PRIDE as well as to iProX. JPOSTdb [https://globe.jpostdb.org/] held 66 human, 25 mouse and 12 bacterial datasets.
Highlights of Progress from the B/D-HPP
The 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 26
Web tools for computational bibliometric analyses provide researchers prioritized lists of proteins in relation to particular organ systems 56 or disease categories 57 , and metabolites or chemicals 58 . In the annual survey of B/D teams, 13 responded that they are using (11) or planning to use (2) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 27 human HBV-associated HCC 64 and a mouse model of metabolic syndrome and fatty liver 65 . A major analysis of patients with early-stage hepatocellular cancers delineated three subtypes, notably S-III with high expression of sterol-O-acyl transferase (SOAT1), which is well-suited for targeted therapy, as demonstrated in xenograft models 55 .
PTMs represent a functional regulatory level that is central to understanding progression of diseases and to define novel therapeutic targets. Cross-talk across different PTMs in the context of cardiovascular physiopathology has been addressed 66 .
A total of 1655 proteins with 3324 oxidized cysteine sites were identified in a mouse cardiac hypertrophy model 67 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 cell line panel 75 . Gut microbiota have been investigated increasingly as a complex community that influences many aspects of human physiology and disease; the platform iMetaLab (http://imetalab.ca) facilitates functional studies of microbiota 76 . A key need in proteomic workflows is format and data analysis standardization; an example is the Minimal Information About an Immuno-Peptidomics Experiment (MIAIPE) guidelines 77 .
Finally, an interlaboratory study to assess the performance of glycoproteomics software for automated intact N-and O-glycopeptide identification from high resolution MS/MS spectral data is ongoing. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 29
The functional annotation of the human proteome requires a collaborative effort.
Fertilization of interactions across C-HPP and B/D-HPP teams 21, 78 to share resources and knowledge will help decipher the code of life and set the basis for future molecular precision medicine.
Highlights from the Human Protein Atlas
During 2018, the Human Protein Atlas (HPA) 79 released its version 18.1 that summarizes data from 26 000 antibodies targeting proteins from 17 000 human proteincoding genes. There is continuously growing global interest with 150 000 web visitors per month. The latest update included interactive survival scatter plots as part of the Pathology Atlas 80 . The Cell Atlas 81 is being recognized in other international projects, such as the Human Cell Atlas 82 , as well as deep learning and citizen science projects 83 .
HPA continues to enhance its work on antibody validation 84 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 30 for enrichment and detection of 120 proteins in human EDTA-plasma; most of the antibodies co-enriched other proteins besides the intended target, due to sequence homology 86 .
During 2019, the HPA plans to release three new components focusing on blood, the brain, and metabolism. In addition, HPA is combining mRNA expression data obtained from human tissues that are currently derived from different types of sequencing data; the harmonized RNA expression data will be a valuable reference resource for neXtProt Protein Evidence curation. A quantitative paired analysis of the proteome and transcriptome abundance for 29 healthy human tissues identified 13,640 proteins, but only 37 without prior protein level evidence. Hundreds of proteins were not detected even when the corresponding mRNAs were highly expressed, particularly in testis (PXD010154) 87 . These findings, and many others, will be captured for standardized reanalysis with the PeptideAtlas TransProteomicPipeline to be included in PeptideAtlas 2020-01 and incorporated into neXtProt release 2020-01. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 analysis of under-studied specimen types. Since 2016 there has been a surprisingly linear decrease in the number of missing proteins, which is likely to continue, though a hard core of perhaps 1000 predicted proteins may be so low in abundance, so unusual in the sites or conditions of expression, or so unsuited to detection that they will be "out of reach." We suspected that we were approaching the limit 2-3 years ago, but the pace of progress has not diminished. Over the next few years we will clarify that question while 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 enhancing our knowledge of the proteins and stimulating the broader and broader use of proteomics in biomedical research. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Page 33 of 47
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